Nieuws en video's - UCB - Pagina 4

UCB to Present Eight Bimekizumab Abstracts at AAD 2023 with Results from Studies in Psoriasis, Psoriatic Arthritis, and Hidradenitis Suppurativa PR Newswire BRUSSELS and ATLANTA, March 16, 2023 Phase 3 data on investigational bimekizumab in the treatment of adults with moderate to severe hidradenitis suppurativa to be presented as a late-breaking platform presentation BRUSSELS and ATLANTA , March 16, 2023 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced that it will...

Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis PR Newswire BRUSSELS and ATLANTA, Jan. 18, 2023 Publication of 24-week results from the BE MOBILE 1 and BE MOBILE 2 studies, evaluating bimekizumab, an IL-17A and IL-17F inhibitor, across the full spectrum of axial spondyloarthritis BRUSSELS and ATLANTA , Jan. 18, 2023 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced that Annals of the Rheumatic Diseases has...

UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review PR Newswire BRUSSELS and ATLANTA, Jan. 6, 2023 Biologic License Application (BLA) designated Priority Review by FDA and seeks approval for rozanolixizumab for the treatment of adults with generalized myasthenia gravis (gMG) who are anti-acetycholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive Rozanolixizumab FDA Priority...

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa PR Newswire BRUSSELS and ATLANTA, Dec. 9, 2022 Top-line results show that the two Phase 3 studies, BE HEARD I and BE HEARD II, met their primary and key secondary endpoints with statistical significance and consistent clinical relevance First Phase 3 evidence to suggest that targeting IL-17F in addition to IL-17A may be a promising treatment approach in adults with moderate to severe hidradenitis suppurativa...

The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis PR Newswire BRUSSELS and ATLANTA, Dec. 7, 2022 Two articles report results from the Phase 3 BE OPTIMAL and BE COMPLETE studies evaluating bimekizumab, an investigational, selective inhibitor of IL-17A and IL-17F, in patients with psoriatic arthritis BRUSSELS and ATLANTA , Dec. 7, 2022 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced that The Lancet has published two articles detailing...

UCB to present data at the American Epilepsy Society 76th Annual Meeting 2022 supporting a decades-long commitment to transforming epilepsy care PR Newswire ATLANTA, Dec. 1, 2022 21 scientific presentations, including 7 late breakers, showcase the breadth of UCB's portfolio, reinforcing commitment to improving the lives of people living with epilepsy New data include insights into the efficacy and safety profile of BRIVIACT ® (brivaracetam) CV, FINTEPLA ® (fenfluramine) CIV, and VIMPAT ®...

Epilepsia Publishes Interim Results of Open-Label Extension Study of FINTEPLA® (fenfluramine) Oral Solution in Patients with Lennox-Gastaut Syndrome (LGS) PR Newswire ATLANTA, Nov. 23, 2022 Peer-reviewed results from the Phase 3 open-label extension study of FINTEPLA ® in LGS provide significant reduction in the frequency of multiple seizure types associated with a drop or fall for 15 months, including tonic and generalized tonic-clonic seizures 1 The cardiovascular safety in this study...

UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients PR Newswire BRUSSELS and ATLANTA, Nov. 14, 2022 New drug application (NDA) for zilucoplan seeks approval for the treatment of generalized myasthenia gravis (gMG) in adult patients who are acetylcholine receptor antibody positive (AChR-Ab+) Acceptance by U.S. Food and Drug Administration (FDA) follows the recent European Medicines...

Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis PR Newswire BRUSSELS and ATLANTA, Nov. 10, 2022 New late-breaking 52-week data from Phase 3 bimekizumab investigational studies in psoriatic arthritis and across the spectrum of axial spondyloarthritis, including non-radiographic axial spondyloarthritis and ankylosing spondylitis, presented at ACR Convergence 2022 In BE...

UCB Reinforces Commitment to Rheumatology With 15 Abstracts Including New Late-Breaking Data at ACR Convergence 2022 PR Newswire BRUSSELS and ATLANTA, Nov. 8, 2022 Late-breaking 52-week data on investigational bimekizumab in the treatment of adults with active psoriatic arthritis and active axial spondyloarthritis to be presented New data on CIMZIA ® (certolizumab pegol) and bimekizumab underscore UCB's commitment to innovative research in rheumatology BRUSSELS and ATLANTA , Nov. 8, 2022...

UCB U.S. HEADQUARTERS IN ATLANTA AWARDED PRESTIGIOUS LEED GOLD AND WELL PLATINUM CERTIFICATIONS PR Newswire ATLANTA, Sept. 26, 2022 UCB's Atlanta Warehouse is the first dually certified WELL Platinum and LEED Gold pharmaceutical project in the world and the first WELL Platinum building in Georgia Together, the premier standards for green building and enhancing people's health and well-being embody UCB's ongoing commitment to sustainability ATLANTA , Sept. 26, 2022 /PRNewswire/ -- UCB, a global...

UCB presents latest data from generalized myasthenia gravis portfolio at AANEM meeting PR Newswire BRUSSELS, Belgium, Sept. 22, 2022 Results presented across UCB's generalized myasthenia gravis (gMG) development program builds the body of evidence around the complexities of gMG Presentations to include data from the Phase 3 MycarinG study of rozanolixizumab as well as the Phase 3 RAISE and RAISE-XT studies of zilucoplan BRUSSELS, Belgium , Sept. 22, 2022 /PRNewswire/ -- UCB, a global...

New Three-Year Bimekizumab Data Reinforce Long-Term Maintenance of Complete Skin Clearance in Moderate to Severe Plaque Psoriasis PR Newswire BRUSSELS and ATLANTA, Sept. 7, 2022 Three-year data from the BE BRIGHT open-label extension study are being presented at the 31st EADV Congress Over eight out of 10 patients who achieved complete skin clearance (PASI 100) at week 16 maintained PASI 100 responses and health-related quality of life outcomes through to three years Analysis of pooled safety...

UCB Showcases Strength of the Expanding Dermatology Portfolio at the 31st EADV Congress PR Newswire BRUSSELS and ATLANTA, Sept. 1, 2022 20 abstracts highlight research in key disease areas including psoriasis and psoriatic arthritis New three-year data to be presented on bimekizumab in the treatment of moderate to severe plaque psoriasis BRUSSELS and ATLANTA , Sept. 1, 2022 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced that it will present 20 abstracts across its...

UCB Partners in Health Economics and Outcomes Research to Evolve Solutions for Seizure Clusters PR Newswire ATLANTA, Aug. 17, 2022 Through collaborations with Le Bonheur Children's Hospital, the Wisconsin Health Information Organization, and Yale University , UCB seeks to further understand the economic and clinical impacts of undertreating seizure clusters and explore drivers of better outcomes The impact of seizure clusters on patient and caregiver quality of life is an understudied area of...

First Presentations of Phase 3 Data for Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022 PR Newswire BRUSSELS and ATLANTA, May 23, 2022 New data from BE MOBILE 1 and BE MOBILE 2 show that bimekizumab achieved consistent improvements versus placebo in signs and symptoms across the full spectrum of axial spondyloarthritis (axSpA), including non-radiographic axSpA (nr-axSpA) and ankylosing spondylitis (AS) Treatment with bimekizumab delivered clinically...

UCB Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to be Presented at EULAR 2022 PR Newswire BRUSSELS and ATLANTA, May 23, 2022 First presentations from the BE OPTIMAL and BE COMPLETE studies evaluating bimekizumab in the treatment of adults with active psoriatic arthritis who were biologic-naïve and TNF-inadequate responders, respectively A higher proportion of patients treated with bimekizumab vs. placebo achieved improvements in joint symptoms at...

UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis PR Newswire BRUSSELS and ATLANTA, May 10, 2022 Phase 3 RAISE and MycarinG studies in generalized myasthenia gravis (gMG) show zilucoplan and rozanolixizumab improve gMG-specific outcomes with consistent statistical significance and clinical relevance Regulatory submissions for zilucoplan and rozanolixizumab are planned for later this year Findings from a real-world smartphone data...

JAMA Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of FINTEPLA® (fenfluramine) Oral Solution in Lennox-Gastaut Syndrome (LGS) PR Newswire BRUSSELS and ATLANTA, May 2, 2022 Primary endpoint was met demonstrating that FINTEPLA, as adjunctive treatment, is effective in significantly reducing the frequency of drop seizures in LGS patients compared to placebo 1 The peer-reviewed published data reinforce the clinical profile of FINTEPLA and its value as a new and important...

UCB Showcases Strength of Broad Neurology Portfolio at 74th American Academy of Neurology (AAN) Annual Meeting PR Newswire BRUSSELS, Belgium and ATLANTA, Ga., April 1, 2022 Scientific presentations illustrate UCB's commitment to addressing unmet needs of people living with a broad range of serious neurological diseases New data focused on epilepsy and Parkinson's disease (PD), including real-world use of BRIVIACT ® (brivaracetam) CV, long-term use of FINTEPLA ® (fenfluramine) CIV (Lennox...